TENX stock forecast
Our latest prediction for Tenax Therapeutics, Inc.'s stock price was made on the Sept. 8, 2020 when the stock price was at 1.42$.
In the short term (2weeks), TENX's stock price should outperform the market by 6.54%. During that period the price should oscillate between -11.09% and +17.66%.
In the medium term (3months), TENX's stock price should outperform the market by 8.17%. During that period the price should oscillate between -46.47% and +54.24%.Get email alerts
Create a solid portfolio with TENX
About Tenax Therapeutics, Inc.
Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The company has a world-class scientific advisory team, including recognized global experts in pulmonary hypertension. The company owns North American rights to develop and commercialize levosimendan and has recently released topline data regarding its Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF). The company was founded on May 26, 1967 and is headquartered in Morrisville, NC.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -1.34$ per share.
The book value per share is 0.24$
Three months stock forecastSept. 8, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|